vs
珐博进（KYNB）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是珐博进的2.0倍（$50.3M vs $25.4M），READING INTERNATIONAL INC净利率更高（-5.1% vs -129.8%，领先124.7%），READING INTERNATIONAL INC同比增速更快（-14.2% vs -29.9%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $-59.3M），过去两年READING INTERNATIONAL INC的营收复合增速更高（5.6% vs -7.8%）
珐博进是一家生物制药企业，专注于纤维化疾病、贫血、肿瘤领域创新疗法的研发与商业化，核心产品罗沙司他已在中国、日本等多个市场获批上市，为患者提供全新治疗选择。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
KYNB vs RDI — 直观对比
营收规模更大
RDI
是对方的2.0倍
$25.4M
营收增速更快
RDI
高出15.7%
-29.9%
净利率更高
RDI
高出124.7%
-129.8%
自由现金流更多
RDI
多$63.4M
$-59.3M
两年增速更快
RDI
近两年复合增速
-7.8%
损益表 — Q1 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.4M | $50.3M |
| 净利润 | $-32.9M | $-2.6M |
| 毛利率 | 15.9% | — |
| 营业利润率 | -193.9% | -1.9% |
| 净利率 | -129.8% | -5.1% |
| 营收同比 | -29.9% | -14.2% |
| 净利润同比 | 57.1% | -14.5% |
| 每股收益（稀释后） | $-0.33 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KYNBRDI
| Q4 25 | — | $50.3M | ||
| Q3 25 | — | $52.2M | ||
| Q2 25 | — | $60.4M | ||
| Q1 25 | — | $40.2M | ||
| Q4 24 | — | $58.6M | ||
| Q3 24 | — | $60.1M | ||
| Q2 24 | — | $46.8M | ||
| Q1 24 | $25.4M | $45.1M |
净利润KYNBRDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | — | $-7.0M | ||
| Q2 24 | — | $-12.8M | ||
| Q1 24 | $-32.9M | $-13.2M |
毛利率KYNBRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 15.9% | — |
营业利润率KYNBRDI
| Q4 25 | — | -1.9% | ||
| Q3 25 | — | -0.6% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | -17.2% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | -0.6% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | -193.9% | -16.7% |
净利率KYNBRDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | — | -8.0% | ||
| Q2 25 | — | -4.4% | ||
| Q1 25 | — | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | — | -11.7% | ||
| Q2 24 | — | -27.4% | ||
| Q1 24 | -129.8% | -29.4% |
每股收益（稀释后）KYNBRDI
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $-0.18 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $-0.57 | ||
| Q1 24 | $-0.33 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.6M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $-228.1M | $-18.2M |
| 总资产 | $365.9M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KYNBRDI
| Q4 25 | — | $10.5M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $5.9M | ||
| Q4 24 | — | $12.4M | ||
| Q3 24 | — | $10.1M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | $177.6M | $7.5M |
总债务KYNBRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益KYNBRDI
| Q4 25 | — | $-18.2M | ||
| Q3 25 | — | $-12.1M | ||
| Q2 25 | — | $-7.7M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $-4.4M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | $-228.1M | $18.0M |
总资产KYNBRDI
| Q4 25 | — | $434.9M | ||
| Q3 25 | — | $435.2M | ||
| Q2 25 | — | $438.1M | ||
| Q1 25 | — | $441.0M | ||
| Q4 24 | — | $471.0M | ||
| Q3 24 | — | $495.7M | ||
| Q2 24 | — | $494.9M | ||
| Q1 24 | $365.9M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.3M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $-59.3M | $4.1M |
| 自由现金流率自由现金流/营收 | -233.9% | 8.2% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-274.7M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流KYNBRDI
| Q4 25 | — | $4.3M | ||
| Q3 25 | — | $295.0K | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | — | $-7.7M | ||
| Q4 24 | — | $8.0M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $-10.4M | ||
| Q1 24 | $-59.3M | $-2.8M |
自由现金流KYNBRDI
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $-246.0K | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $-8.0M | ||
| Q4 24 | — | $7.0M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | $-59.3M | $-4.7M |
自由现金流率KYNBRDI
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | -0.5% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | — | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | -233.9% | -10.4% |
资本支出强度KYNBRDI
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | 0.1% | 4.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
